Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Longeveron Partners with Biorasi for Alzheimer’s Trial | Contract Pharma

What are you searching for?

Sign in
Breaking News

Longeveron Partners with Biorasi for Alzheimer’s Trial

Biorasi to help conduct its Phase 2 clinical trial evaluating Lomecel-B infusion in Alzheimer’s Disease subjects.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic age-related and life-threatening conditions, has selected Biorasi LLC as its clinical research organization (CRO) to help conduct its Phase 2 clinical trial evaluating Lomecel-B infusion in Alzheimer’s Disease (AD) subjects.   
 
Biorasi has extensive experience in the management and execution of neurology clinical studies, and in phase I through IV trials in the U.S. and globally.
 
“Partnering with Biorasi for Longeveron’s next Phase 2 AD trial will help continue to advance the development of Lomecel-B for the treatment of Alzheimer’s disease,” said Kevin N. Ramdas, MD, MPH, Director, Medical Affairs at Longeveron. “We look forward to initiating the trial by year-end, or in the first quarter of 2022.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters